Form Type: 4

SEC EDGAR Link
Accession Number:0000899243-19-029428
Date:2019-12-17
Issuer: SPARK THERAPEUTICS, INC. (ONCE)
Original Submission Date:

Reporting Person:

EKMAN LARS
3737 MARKET STREET
SUITE 1300 PHILADELPHIA, PA 19104

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-12-17 U 3,000 d $114.50 0 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 81.53 2019-12-17 deemed execution date D 4,000 (d) 2028-05-29 common stock 4,000 $81.53 0 direct
STOCK OPTION (RIGHT TO BUY) 50.93 2019-12-17 deemed execution date D 4,000 (d) 2027-05-30 common stock 4,000 $50.93 0 direct
STOCK OPTION (RIGHT TO BUY) 56.22 2019-12-17 deemed execution date D 6,000 (d) 2026-05-31 common stock 6,000 $56.22 0 direct
STOCK OPTION (RIGHT TO BUY) 3.45 2019-12-17 deemed execution date D 37,203 (d) 2024-08-11 common stock 37,203 $3.45 0 direct
Footnotes
IDfootnote
f1 disposed of pursuant to the agreement and plan of merger, dated february 22, 2019, by and between spark therapeutics, inc. ("spark"), roche holdings, inc. ("roche") and 022019 merger subsidiary, inc. ("merger sub") (the "merger agreement" and the transactions contemplated thereby, the "merger"), whereby roche caused merger sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of spark, at a price of $114.50 per share. on december 17, 2019, merger sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
f2 pursuant to the terms of the merger agreement, immediately prior to the effective time of the merger, each outstanding spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
WhaleWisdom Logo

Elevate your investments